Thyroid eye disease (TED) therapy Tepezza – the very best asset in Amgen's $26 billion takeover of Horizon in 2023 – may be struggling with Competitiveness from A better-to-dose alternate from Sling Therapeutics. Even though The mixture was resolute Harmless, the ex